However, the knowledge about the PD-L2 regulatory network is relatively limited, and there are currently no clinical practices or trials involving immunotherapy regimens specifically targeting PD-L2 in CRC. This evidence concerns the gene PDCD1LG2 and colorectal carcinoma.